FINHUB Insights

VTRS · Q2 FY25 · Apr 1 – Jun 30, 2025

Viatris Q2 FY25: where the revenue came from and where it went

Viatris Q2 FY25: revenue $3.6B (−6% year over year). Net profit $0B. Largest cohort Brands $2.3B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2025
Reported
Aug 7, 2025 10-Q
Sankey diagram of Viatris's income statement for Q2 FY25: revenue of $3.6 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.6B −6% year over year
Gross profit$1.3B 37% margin
Operating profit$0.2B 7% margin
Net profit$0B 0% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
ItemValueShare of revenueYear over year
Revenue 3.6 100% −6%
Brands 2.3 64% −3%
Lipitor 0.4 11%
Norvasc 0.2 6%
Epi Pen Auto Injectors 0.1 3%
Lyrica 0.1 3%
Other 0.1 3%
Viagra 0.1 3%
Celebrex 0.1 3%
Cost of revenue−2.261%
Gross profit1.337% margin−1pp
Research & development−0.26%+1pp
SG&A−0.926%−1pp
Operating profit0.27% margin+13pp
Interest & other costs−0.4
Net profit00%+0pp
Filing on EDGAR More quarters of VTRS

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters